An approach to primary bone tumors

This article is designed to provide the busy, practicing physician with the essential information needed to approach the patient with a primary bone tumor. An algorithm provides a suitable method of assessing most patients with bone tumors, recognizing slight modification is necessary in each case. Following this approach should allow successful accomplishment of the therapeutic triad: (1) do not "over-treat" a benign bone tumor, (2) do not "under-treat" a malignant bone tumor, and (3) do not misdirect the biopsy approach to the lesion so as to convert a more conservative operation into a more radical operation.     

Magnetic resonance imaging in primary bone tumors

MRI plays a major role in the evaluation and treatment planning of bone tumors. It should be used following plain films and before biopsy. The MR appearance of most tumors is nonspecific; however, the entire extent of the tumor and its relationship to adjacent structures can be determined at MRI providing a road map for the surgeon. The role of dynamic enhancement is evolving and has not yet been determined.     

Computed tomography in malignant primary bone tumors

The importance of computed tomography is examined in malignant primary bone tumours using a strongly defined examination group of 13 Patients (six Ewing's-sarcomas, five osteosarcomas, one chondrosarcoma and one spindle-shaped cell sarcoma). Computed tomography is judged superior compared to plain radiographs in recognition of bone marrow infiltration and presentation of parosteal tumour parts as well as in analysis of tissue components of tumours, CT is especially suitable for therapy planning and evaluating response to therapy. CT does not provide sufficient diagnostic information to determine dignity and exact diagnosis of bone tumours.     

Imaging of primary bone tumors of the spine

Primary tumors of the spine are relatively infrequent lesions compared with metastatic disease, multiple myeloma, and lymphoma. A wide variety of benign and malignant neoplasms can involve the spine. The imaging features of these lesions are often characteristic. We present an overview of the imaging modalities in primary tumors of the spine in order to provide a useful tool in current radiologic practice. The role of CT and MRI is discussed.     

Magnetic resonance imaging of primary malignant bone tumors

The authors report a retrospective study that suggests that MRI may be superior to CT for the preoperative evaluation of bone tumors.     

Magnetic resonance imaging of primary malignant bone tumors

The authors find that MRI yields more useful information in a single study than CT, Tc scanning or angiography; they use it as the primary local staging procedure in malignant bone tumors.     

Computed tomography of primary bone tumors in children

The diagnostic value of CT examination in 21 children with 14 malignant and 7 benign bone neoplasias was evaluated. CT contributed in 72%; mainly in malignant conditions it was superior to other diagnostic techniques and demonstrated the exact intra- as well as the extraosseous extension. The cross sectional display facilitated evaluation of complex anatomic structures. Monitoring the treatment was easily performed by CT follow-up studies. However, 28% of all the examinations were not contributary, this group mainly including benign lesions.     

MRI in primary bone tumors: therapeutic implications

The accuracy of preoperative MRI in detecting tumor extent has been evaluated in 35 patients with primary bone neoplasms; intra-osseous extent was measured on MR images and compared with macroslides of surgical specimens in 26 cases. An almost completely accurate prediction of tumor size was obtained with the combined employment of Spin-Echo (SE) and Short Inversion Time Inversion Recovery (STIR) sequences in the various tumors, with the exception of two Ewing's sarcomas. Changes in Signal Intensity (SI) and tumor morphology were identified in those cases which had undergone presurgical chemotherapy; the reduction in SI and in tumor size or the appearance of a more homogeneous signal was correlated with a positive response to cytotoxic therapy. MR imaging fully satisfies surgeon's preoperative requirements in the assessment of therapy-responding neoplasms as well as in local tumor staging in all types of neoplasms, with the exception of Ewing's sarcoma.     

Imaging of primary malignant bone tumors (nonhematological)

Primary malignant bone tumors are uncommon and are diagnosed typically based on radiographic and microscopic findings combined with clinical and demographic features. CT and MR imaging scans are useful in further staging the tumors by determining intraosseous and extraosseous spread.     

MR imaging of primary bone and soft tissue tumors

MR imaging of 131 cases with pathologically confirmed primary bone and soft tissue tumors were studied. They included 44 bone tumors (25 benign tumors, 19 malignant tumors) and 87 soft tissue tumors (55 benign tumors, 32 malignant tumors). MR imaging was performed on 0.5T, superconductive magnet system. All tumors were evaluated with T1-weighted, T2-weighted and STIR images. In some cases, contrast enhanced MR imaging with Gd-DTPA was applied. MR imaging was proving to be a valuable technique in the evaluation of patients with primary bone and soft tissue tumors. MR imaging was superior to the other modalities in delineating the extent of the tumor and their relation to surrounding structures in all cases. However, plain radiography and CT were more useful for evaluation of calcification, ossification, cortical destruction and endosteal/periosteal reaction than MR imaging. Direct sagittal and coronal images from MR imaging added accurate assessment for the relation between the tumor and their adjacent structures. MR imaging was of limited value in distinguishing benign from malignant tumors with the demonstration of tumor structures only, especially soft tissue tumors. But in bone and soft tissue tumors which have specific morphologic features and intensity patterns, MR imaging was very useful for diagnosis.     

MRI and CT evaluation of primary bone and soft-tissue tumors

Twenty-six patients with primary tumors of bone or somatic soft tissues underwent both magnetic resonance imaging (MRI) and computed tomography (CT); 15 of the patients had radionuclide bone scans as well. Only in a minority of cases did these tomographic methods provide information needed for diagnosis that could not be derived from the plain radiographs alone; however, for assessing the extent of the disease, both CT and MRI proved very valuable, particularly MRI. Specifically, MRI was superior to CT in delineating the extent of the neoplasms and their relation to surrounding structures in 21 of the patients, equal in four, and inferior in only one. Furthermore, in the 13 patients with tumors of long bone, MRI was judged superior to CT in visualizing marrow abnormality in 12 cases, and equal in only one case. Radionuclide scans demonstrated the lesions in 14 of the 15 cases; its primary utility was in excluding additional lesions. It is concluded that for these patients, MRI was the imaging method of choice in assessing the extent of bone and soft-tissue tumors.     

Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors

PURPOSE: To determine the diagnostic accuracy of image-guided percutaneous biopsy in 110 primary bone tumors of varying internal compositions. MATERIALS AND METHODS: One hundred ten consecutive patients with primary bone tumors underwent biopsy with computed tomography (CT) or fluoroscopy. Ninety-one patients underwent surgical follow-up and 19 received medical treatment and underwent subsequent imaging studies. Final analysis of bone biopsy results included tumor type, malignancy, final tumor grade, biopsy complications, and effect on eventual treatment outcome. RESULTS: Seventy-seven tumors were malignant and 33 were benign. Most common tumors at biopsy were osteosarcoma (n = 20), lymphoma (n = 18), chondrosarcoma (n = 16), and giant cell tumor (n = 16). Correct final diagnosis was attained in 97 (88%) patients. Sixty-three lesions were solid nonsclerotic; 26, sclerotic; and 21, lytic with cystic centers containing internal areas of fluid, hemorrhage, or necrosis. In six of 21 lesions with a predominant cystic internal composition, problems occurred in determining a final diagnosis. In 13 patients, definite correct diagnosis was not obtained with initial percutaneous bone biopsy. Of these patients, benign bone tumors were better defined with surgical specimens in seven, a diagnosis of malignancy was changed to that of another malignancy in four, and the diagnosis was changed from benign to malignant in two. Nine patients underwent open surgical biopsy. Seven of the difficult cases were of cystic tumors with hemorrhagic fluid levels visible at CT or magnetic resonance imaging. The only complication was a small hematoma. CONCLUSION: Percutaneous biopsy of primary bone tumors is safe and accurate for diagnosis and grade of specific tumor. In cases with nondiagnostic biopsy, open-procedure biopsy is likely to be associated with similar diagnostic difficulties.     

CT灌注成像对单发骨转移瘤与原发恶性骨肿瘤的鉴别

目的 探讨CT灌注成像在单发骨转移瘤与原发恶性骨肿瘤鉴别诊断中价值.方法 回顾性分析经手术病理证实的14例单发骨转移瘤和15例原发恶性骨肿瘤的CT灌注检查.结果 单发骨转移瘤和原发恶性骨肿瘤在灌注参数方面无明显不同,但在是否伴有高灌注的软组织肿块或低灌注的中央坏死区方面有明显不同:单发骨转移瘤是2例(14.3%),原发恶性骨肿瘤是13例(86.7%).结论 CT灌注成像有助于鉴别单发骨转移瘤与原发恶性骨肿瘤,可以详细全面提供医生制定手术计划所需要的骨肿瘤的性质和血供情况的信息.     

Rationale for the use of bone scans in selected metastatic and primary bone tumors

Since the introduction of bone scans in 1951, there have been many studies comparing biologic and physical characteristics of new bone-imaging agents and the results of scintigraphy and radiology in large numbers of patients. Relatively speaking, there have been fewer studies detailing the health benefits and financial cost associated with the use of skeletal scintigraphy. This review concerns these aspects in patients with malignancies of various sites and stages. About 2% of patients with stage I or II breast cancer have bone metastases at the time they first present, whereas nearly 28% of patients with stage III disease have bone metastases. A large percentage of patients with initially negative scans develop bone metastases during the first 3--4 yr; many of them develop them within the first 12--18 mo after initial diagnosis. For patients with lung cancer, the use of bone scans in staging their disease is somewhat controversial. Several studies indicate that the yield of positive bone scans may range from as low as 2% to as high as 35%. Data on the use of bone scans in staging prostatic cancer initially are similar to those in patients with breast cancer, that is, yields of 7% in patients with stage I or II disease and a yield of about 20% with stage III disease. Children with osteosarcoma or Ewing's sarcoma rarely have bone disease distant from the site of their primary bone lesion at presentation. However, a large percentage of them (30%--40% or so) develop bone metastases during the follow-up period. As in the case with patients with breast cancer, about half of these bone metastases are evident by 12--18 mo.     

Noninvasive grading of musculoskeletal tumors using PET

Twenty-five patients with mass lesions involving the musculoskeletal system were studied with positron emission tomography (PET) in order to determine if a relationship exists between histologic grade and tumor uptake of [fluorine-18]2-deoxy-2-fluoro-D-glucose (FDG). There were 6 benign lesions and 19 malignant lesions of various grades. A high correlation (Rho = 0.83) was found between the normalized uptake of tracer and the NCl grade. The high-grade malignancies had significantly greater (p = 0.0091) uptake of FDG than the combination of benign lesions and low-grade malignancies. All lesions with a normalized uptake value of 1.6 or greater were high-grade, while all lesions less than 1.6 represented either benign tumors or low grade malignancies. This strong relationship between FDG uptake and grade among neoplasms from a wide variety of cell types within a single organ system suggests that the technique may be useful in predicting grade even when the cell type is unknown.     

Preoperative embolization of primary bone tumors:A case control study

AIM:To study the safety and effectiveness of preoperative embolization of primary bone tumors in relation to intraoperative blood loss,intraoperative blood transfusion volume and surgical time.METHODS:Thirty-three patients underwent preoperative embolization of primary tumors of extremities,hip or vertebrae before resection and stabilization.The primary osseous tumors included giant cell tumors,aneurysmal bone cyst,osteoblastoma,chondroblastoma and chondrosarcoma.Twenty-six patients were included for the statistical analysis(embolization group)as they were operated within 0-48 h within preoperative embolization.A control group(non-embolization group,n = 28)with bone tumor having similar histological diagnosis and operated without embolization was retrieved from hospital record for statistical comparison.RESULTS:The mean intraoperative blood loss was 1300 mL(250-2900 mL),the mean intraoperative blood transfusion was 700 m L(0-1400 m L)and the mean surgical time was 221 ± 76.7 min for embolization group(group Ⅰ,n = 26).Non-embolization group(group Ⅱ,n = 28),the mean intraoperative blood loss was 1800 m L(800-6000 m L),the mean intraoperative blood transfusion was 1400 mL(700-8400 mL)and the meansurgical time was 250 ± 69.7 min.On comparison,statistically significant(P < 0.001)difference was found between embolisation group and non-embolisation group for the amount of blood loss and requirement of blood transfusion.There was no statistical difference between the two groups for the surgical time.No patients developed any angiography or embolization related complications.CONCLUSION:Preoperative embolization of bone tumors is a safe and effective adjunct to the surgical management of primary bone tumors that leads to reduction in intraoperative blood loss and blood transfusion volume.